Indaptus Therapeutics INDP Stock Is It a Good Entry Point Indaptus Therapeutics misses EPS views no revenue TACOU Berto leadership lays out key longterm expansion priorities with the release of its latest quarterly earnings report What is impacting BioHarvest BHST stock performance Q1 2025 Profit Disappoints PCSA Processa Pharmaceuticals posts worsethanexpected Q4 2025 EPS results that miss estimates by 68 percent as shares edge 033 percent lower Is Dare Bio DARE stock gaining momentum Q4 2025 EPS Beats Forecasts